A Phase 3 Multicenter, Placebo-controlled, Double-blind, Randomized-withdrawal Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Phase 3 Multicenter, Placebo-controlled, Double-blind, Randomized-withdrawal Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms PURSUIT-J
  • Sponsors Janssen Pharmaceutical KK
  • Most Recent Events

    • 19 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 May 2014 Planned End Date changed from 1 Sep 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top